This study could significantly impact Regeneron and Intellia’s stock performance by showcasing their innovative approach to gene therapy. Success in this study may enhance investor sentiment and ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals is conducting a ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large-cap stocks ...

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD due to inspection findings at a Catalent manufacturing site, despite ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57. The company reported sales ...

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand for its blockbuster eczema treatment, Dupixent, sending its shares up ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug Dupixent, and said it does not expect a material impact from tariffs on ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click here to read why REGN is a Buy.